Work

Analysis of Japanese patients from the AUGMENT phase III study of lenalidomide + rituximab (R2) vs. rituximab + placebo in relapsed/refractory indolent non-Hodgkin lymphoma

Year: 2019

Type: article

Source: International Journal of Hematology

DOI: 10.1007/s12185-019-02802-y

Authors: Koji Izutsu, Yosuke Minami, Noriko Fukuhara, Yasuhito Terui, Tatsuro Jo, Go Yamamoto, Takayuki Ishikawa, Tsutomu Kobayashi, Toru Kiguchi, Hirokazu Nagai, Tomoko Ohtsu, Stacey Kalambakas, Pierre Fustier, Shuichi Midorikawa, Kensei Tobinai

Institutions: National Cancer Center Hospital, National Cancer Center Hospital East, Tohoku University Hospital, The Cancer Institute Hospital, Japanese Foundation For Cancer Research, Japanese Red Cross Nagasaki Genbaku Hospital, Toranomon Hospital, Kobe City Medical Center General Hospital, Kyoto Prefectural University of Medicine, Chugoku Central Hospital, Nagoya Medical Center, Celgene (United States), Celgene (Switzerland)

Language: English

Topic: Lymphoma Diagnosis and Treatment

Subfield: Pathology and Forensic Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: Celgene

OpenAlex ID: W2995841997

FWCI: 1.414

Cites: 31

Cited by: 6

Related to: 10